Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
Oragenics (NYSE American: OGEN) announced its participation in the 15th Annual Traumatic Brain Injury Conference in Boston, MA on May 5-6, 2025. The company's Chief Clinical Officer, Dr. W. Frank Peacock, will present updates on the HeadSMART II trial, one of the largest U.S. emergency department biomarker discovery studies for mild traumatic brain injury (mTBI).
The study, expected to enroll over 2,000 patients within the next year, is conducted in collaboration with BrainBox Solutions. This partnership aims to develop a comprehensive test-to-treat platform combining BrainBox's diagnostics with Oragenics' intranasal therapeutic candidate, ONP-002.
The conference brings together leaders from academia, industry, government, and military to discuss advances in TBI research and clinical care, focusing on diagnosis, treatment, and long-term outcomes for TBI survivors.
Oragenics (NYSE American: OGEN) ha annunciato la sua partecipazione alla 15ª Conferenza Annuale sul Trauma Cranico a Boston, MA, il 5 e 6 maggio 2025. Il Chief Clinical Officer dell'azienda, il Dr. W. Frank Peacock, presenterà gli aggiornamenti sullo studio HeadSMART II, uno dei più grandi studi statunitensi condotti nei reparti di emergenza per la scoperta di biomarcatori nel trauma cranico lieve (mTBI).
Lo studio, che prevede di arruolare oltre 2.000 pazienti entro il prossimo anno, è realizzato in collaborazione con BrainBox Solutions. Questa partnership mira a sviluppare una piattaforma completa di test e trattamento che unisca la diagnostica di BrainBox con il candidato terapeutico intranasale di Oragenics, ONP-002.
La conferenza riunisce esperti provenienti dal mondo accademico, industriale, governativo e militare per discutere i progressi nella ricerca e nella cura clinica del trauma cranico, con un focus su diagnosi, trattamento e risultati a lungo termine per i sopravvissuti al trauma cranico.
Oragenics (NYSE American: OGEN) anunció su participación en la 15ª Conferencia Anual sobre Lesiones Cerebrales Traumáticas en Boston, MA, los días 5 y 6 de mayo de 2025. El Director Clínico de la compañía, el Dr. W. Frank Peacock, presentará actualizaciones sobre el ensayo HeadSMART II, uno de los estudios más grandes en departamentos de emergencia de EE.UU. para el descubrimiento de biomarcadores en lesiones cerebrales traumáticas leves (mTBI).
El estudio, que se espera reclute a más de 2,000 pacientes en el próximo año, se realiza en colaboración con BrainBox Solutions. Esta alianza busca desarrollar una plataforma integral de prueba y tratamiento que combine el diagnóstico de BrainBox con el candidato terapéutico intranasal de Oragenics, ONP-002.
La conferencia reúne a líderes de la academia, la industria, el gobierno y el ámbito militar para discutir avances en la investigación y atención clínica de las lesiones cerebrales traumáticas, centrándose en el diagnóstico, tratamiento y resultados a largo plazo para los sobrevivientes de TBI.
Oragenics (NYSE American: OGEN)는 2025년 5월 5일부터 6일까지 매사추세츠주 보스턴에서 열리는 제15회 연례 외상성 뇌손상 컨퍼런스에 참가한다고 발표했습니다. 회사의 최고 임상 책임자 Dr. W. Frank Peacock가 경미한 외상성 뇌손상(mTBI)을 위한 미국 내 최대 규모의 응급실 바이오마커 발견 연구 중 하나인 HeadSMART II 임상시험 최신 정보를 발표할 예정입니다.
향후 1년 내 2,000명 이상의 환자 등록이 예상되는 이 연구는 BrainBox Solutions와 협력하여 진행되고 있습니다. 이 파트너십은 BrainBox의 진단기술과 Oragenics의 비강 내 치료 후보물질 ONP-002를 결합한 종합적인 검사-치료 플랫폼 개발을 목표로 합니다.
이번 컨퍼런스는 학계, 산업계, 정부 및 군 관계자들이 모여 외상성 뇌손상 연구 및 임상 치료의 진보를 논의하며, 진단, 치료 및 외상성 뇌손상 생존자의 장기적 결과에 중점을 둡니다.
Oragenics (NYSE American : OGEN) a annoncé sa participation à la 15e Conférence Annuelle sur les Traumatismes Crâniens à Boston, MA, les 5 et 6 mai 2025. Le directeur médical de l'entreprise, le Dr W. Frank Peacock, présentera les dernières avancées de l'essai HeadSMART II, l'une des plus grandes études américaines sur la découverte de biomarqueurs en service d'urgence pour les traumatismes crâniens légers (mTBI).
Cette étude, qui prévoit d'inclure plus de 2 000 patients au cours de l'année à venir, est menée en collaboration avec BrainBox Solutions. Ce partenariat vise à développer une plateforme complète de test et traitement combinant les diagnostics de BrainBox avec le candidat thérapeutique intranasal d'Oragenics, ONP-002.
La conférence rassemble des leaders du monde universitaire, industriel, gouvernemental et militaire pour discuter des avancées en recherche et soins cliniques des traumatismes crâniens, en se concentrant sur le diagnostic, le traitement et les résultats à long terme pour les survivants de TBI.
Oragenics (NYSE American: OGEN) gab seine Teilnahme an der 15. Jahrestagung zur traumatischen Hirnverletzung bekannt, die am 5. und 6. Mai 2025 in Boston, MA, stattfindet. Der Chief Clinical Officer des Unternehmens, Dr. W. Frank Peacock, wird Updates zur HeadSMART II-Studie vorstellen, einer der größten US-Studien zur Entdeckung von Biomarkern bei leichter traumatischer Hirnverletzung (mTBI) in Notaufnahmen.
Die Studie, die innerhalb des nächsten Jahres über 2.000 Patienten einschreiben soll, wird in Zusammenarbeit mit BrainBox Solutions durchgeführt. Diese Partnerschaft zielt darauf ab, eine umfassende Test- und Behandlungsplattform zu entwickeln, die die Diagnostik von BrainBox mit dem intranasalen Therapie-Kandidaten von Oragenics, ONP-002, kombiniert.
Die Konferenz bringt Führungskräfte aus Wissenschaft, Industrie, Regierung und Militär zusammen, um Fortschritte in Forschung und klinischer Versorgung von TBI zu diskutieren, mit Schwerpunkt auf Diagnose, Behandlung und langfristigen Ergebnissen für TBI-Überlebende.
- None.
- None.
SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies for concussion and brain-related conditions, today announced its participation in the 15th Annual Traumatic Brain Injury Conference, taking place May 5-6, 2025 in Boston, MA.
Hosted by Arrowhead Sci-Tech Conferences & Events, the Annual Traumatic Brain Injury Conference brings together global leaders from academia, industry, government, and the military to share the latest advancements in TBI research and clinical care. The event provides a platform for cross-sector collaboration on diagnosis, treatment, and long-term outcomes for TBI survivors.
Oragenics will be represented by Dr. W. Frank Peacock, MD, FACEP, FACC, FESC, Chief Clinical Officer of Oragenics and Professor, Vice Chair for Research at Baylor College of Medicine, presenting, “An Update on HeadSMART II: Advancing Precision Strategies for Traumatic Brain Injury Detection and Management”.
The presentation will highlight data from HeadSMART II, one of the largest ongoing U.S. emergency department prospective biomarker discovery trials for mild traumatic brain injury (mTBI). The study is expected to surpass 2,000 enrolled patients within the next year. Findings from HeadSMART II may significantly reshape the understanding of the mTBI population and influence future clinical trial enrollment strategies in the field.
Oragenics is participating in the HeadSMART II trial in collaboration with BrainBox Solutions, a leader in precision diagnostics for brain injury, as part of its broader commitment to advancing the early detection, treatment, and clinical management of concussions and other brain injuries. This collaboration builds on the strategic partnership announced earlier this year, aimed at creating a comprehensive test-to-treat platform for mild traumatic brain injury by combining BrainBox’s diagnostic technologies with Oragenics’ intranasal therapeutic candidate, ONP-002. Read the full announcement here.
For more information on the conference, visit https://tbiconference.com/
Investor Contact
Rich Cockrell
866.889.1972
ogen@cg.capital
About Oragenics, Inc.
Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders, including its lead candidate, ONP-002, for the treatment of mild traumatic brain injury (mTBI) or concussion. The Company is also advancing proprietary powder formulations and intranasal delivery technology to enhance drug administration. For more information, visit www.oragenics.com.
FAQ
What is the HeadSMART II trial that Oragenics (OGEN) is presenting at the TBI Conference 2025?
How is Oragenics (OGEN) collaborating with BrainBox Solutions for TBI treatment?
When and where is Oragenics (OGEN) presenting at the Traumatic Brain Injury Conference?
What therapeutic candidate is Oragenics (OGEN) developing for brain injury treatment?
Who will represent Oragenics (OGEN) at the 2025 TBI Conference?
